Gilteritinib Fumarate

富马酸吉瑞替尼

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameGilteritinib Fumarate
Drug Alias NameGilteritinibum吉特替尼吉瑞替尼GilteritinibXospata +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAXL receptor tyrosine kinase inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3AXL receptor tyrosine kinase
Therapy Area/IndicationsSolid tumoursRenal InsufficiencyHepatic Insufficiency +[6] 
Global Approved IndicationsLeukemia, Myeloid, Acute
Approved Indications in ChinaLeukemia, Myeloid, Acute
Original Approved Country/TerritoryJapan
Original Approved Date2018/09/21
Country/TerritoryMainland China(BOAO LECHENG)CzechiaBelgium +[32] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesAstellas Pharma Tech Co Ltd Yaizu Technology CenterAstellas Pharma Us IncAstellas Pharma Europe Bv +[7] 
Inactive CompaniesN/A
Active IndicationsRenal InsufficiencyCarcinoma, Non-Small-Cell LungLung Neoplasms +[4] 
Inactive IndicationsSolid tumoursHepatic Insufficiency

Other Information

ATC CodeL01EX13
Related LinksWikipediaDrugBankKEGG